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ABSTRACT
Objectives Nerve growth factor (NGF) is a promising
analgesic target, particularly in osteoarthritis (OA) where
existing therapies are inadequate. We hypothesised that
pain responses to NGF are increased in OA joints. Here,
NGF-evoked pain behaviour was compared in two
rodent models of OA, and possible mechanisms
underlying altered pain responses were examined.
Methods OA was induced in rat knees by meniscal
transection (MNX) or intra-articular monosodium
iodoacetate injection (MIA). Once OA pathology was
fully established (day 20), we assessed pain behaviour
(hindlimb weight-bearing asymmetry and hindpaw
mechanical withdrawal thresholds) evoked by intra-
articular injection of NGF (10 mg). Possible mechanisms
underlying alterations in NGF-induced pain behaviour
were explored using indomethacin pretreatment,
histopathological evaluation of synovitis, and rtPCR for
NGF receptor (tropomyosin receptor kinase (Trk)-A)
expression in dorsal root ganglia (DRG).
Results Both the MIA and MNX models of OA
displayed reduced ipsilateral weight bearing and
hindpaw mechanical withdrawal thresholds, mild
synovitis and increased TrkA expression in DRG. NGF
injection into OA knees produced a prolonged
augmentation of weight-bearing asymmetry, compared
to NGF injection in non-osteoarthritic knees. However,
hindpaw mechanical withdrawal thresholds were not
further decreased by NGF. Pretreatment with
indomethacin attenuated NGF-facilitated weight-bearing
asymmetry and reversed OA-induced ipsilateral TrkA
mRNA up-regulation.
Conclusions OA knees were more sensitive to NGF-
induced pain behaviour compared to non-osteoarthritic
knees. Cyclo-oxygenase products may contribute to
increased TrkA expression during OA development, and
the subsequent increased NGF sensitivity. Treatments
that reduce sensitivity to NGF have potential to improve
OA pain.
BACKGROUND
Pain is the predominant feature of osteoarthritis
(OA),1 and most people with OA continue to
experience pain despite analgesic use. OA pain may
be augmented through multiple mechanisms, both
within the joint and through sensitisation of pain
processing pathways. Synovitis and joint damage
are closely associated with OA pain,2–4 and
cyclo-oxygenase inhibitors and intra-articular
glucocorticosteroid injections can reduce both
inﬂammation and pain in man and in rat OA
models.2 5–7 Inﬂammation contributes to pain ﬂares
in OA, exacerbates articular damage, and may initi-
ate sustained sensitisation that subsequently aug-
ments chronic pain. Unfortunately, the beneﬁts of
anti-inﬂammatory treatments in OA are often
incomplete, not sustained, and may be associated
with signiﬁcant adverse events. There is an urgent
need for new analgesic agents for people with OA.
Nerve growth factor (NGF) plays a key role in
many persistent pain states, notably those asso-
ciated with inﬂammation.8–13 The β subunit of
NGF binds tropomyosin receptor kinase-A (TrkA)
and p75 neurotrophin receptors on sensory nerve
terminals.14 15 Exogenous administration of small
doses of NGF to adult animals and humans can
produce pain and hyperalgesia.16–18 NGF is
up-regulated in human19 and rodent20 osteoarth-
ritic joints and is associated with inﬂammatory cell
inﬁltration of the synovium9 21–23 and subchondral
bone.24 25 Clinical trials with NGF-blocking anti-
bodies indicate NGF makes an important contribu-
tion to OA pain.26 Indeed, the effects in OA appear
superior to those in other chronic pain states, such
as neuropathic pain,27 suggesting a particular con-
tribution of NGF to OA pain. We hypothesised
that the importance of NGF for OA pain may be
due, in part, to increased sensitivity of OA joints to
its pain-augmenting actions and that inﬂammation
may contribute to this increased sensitivity to NGF.
We aimed to determine the effects of
intra-articular NGF injection in normal and osteo-
arthritic rat knees, and to explore possible mechan-
isms underlying any altered sensitivity to NGF by
measuring mRNA expression of the high afﬁnity
NGF receptor, TrkA, and by inhibiting inﬂamma-
tion during OA pathogenesis.
MATERIALS AND METHODS
Animals models of OA
In vivo experiments performed on 7-week-old male
Sprague–Dawley rats (n=8 per group, weighing
200–220 g; Charles River, Kent, UK) were carried
out in accordance with UK Home Ofﬁce regula-
tions and follow the guidelines of the International
Association for the Study of Pain. Rats were housed
under standard conditions under a 12 h light/dark
cycle, with unlimited access to food and water. Rats
were anaesthetised with isoﬂurane (2% in O2) prior
to surgery and intra-articular injections.2 All
outcome measurements were made by an observer
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blinded to treatment. Non-osteoarthritic rats were used as con-
trols. Experimental designs and group sizes are described in
online supplementary ﬁgures S1 and S2.
Induction of OA
OA was induced on day 0 in the left knee by either medial
meniscal transection (MNX)2 or by a single intra-articular injec-
tion of monosodium iodoacetate (MIA; 1 mg/50 mL sterile
0.9% normal saline, pH 7.4). MIA dose was based on previous
studies.28 29 Controls received intra-articular saline injection.
We previously demonstrated that sham-operated controls do not
display pain behaviour, inﬂammation or OA structural changes
beyond 7 days after surgery.30 31
Pharmacological interventions
Intra-articular NGF injection
Rats were given a single 50 mL intra-articular injection into their
left knees of NGF in sterile 0.9% normal saline, pH 7.4, or saline
control. Initial dose–response studies in normal rats used 10 mg,
1 mg or 100 ng of NGF. Subsequent experiments compared the
effects of NGF (10 mg/50 mL) or saline control injected into the
left knee of non-osteoarthritic rats and rats 20 days after OA
induction. By day 20, OA pathology and pain behaviour are
evident in both the MIA and MNX models of OA.2 32
Systemic indomethacin administration
To investigate the contribution of OA-associated synovitis to
altered NGF-induced pain responses, rats with MIA-induced
OA received daily oral gavage with 0.5 mL of either 2 mg/kg
indomethacin or vehicle (sterile 0.9% normal saline, pH 7.4)
from 1 day before OA induction continuing until day 18.
Indomethacin treatment ceased 2 days before NGF injection in
order to avoid any direct effects of indomethacin on pain behav-
iour. This dose of indomethacin showed attenuated pain behav-
iour and inﬂammation in earlier reports.2 33
Pain behaviour and joint swelling
Pain behaviour was measured as hindlimb weight-bearing asym-
metry and as distal allodynia to punctate stimulation of the
hindpaw. The difference in weight bearing (g) between the ipsilat-
eral treated limb and the contralateral control limb was measured
using an incapacitance meter (Linton Instruments, Norfolk, UK) as
the average of ﬁve readings.2 Paw withdrawal thresholds were mea-
sured using a series of von Frey monoﬁlaments (Semmes-Weinstein
monoﬁlaments with bending forces of 1, 1.4, 2, 4, 6, 8, 10 and
15 g) applied in ascending order of bending force to the plantar
surface.32 The paw withdrawal threshold was the lowest weight of
monoﬁlament that elicited a withdrawal reﬂex.
Joint swelling was measured with digital electronic callipers
(Mitutoyo, Andover, UK) as the difference in knee diameter
(millimeters) between the ipsilateral and contralateral knees.
Tissue processing
At the termination of each experiment rats were killed by
asphyxiation in carbon dioxide, and synovia with patellae from
the right and left knees were immediately harvested, embedded
in OCT and snap frozen over melting isopentane. Ipsilateral and
contralateral dorsal root ganglia (DRG) from lumbar regions 1,
2, 3, 4 and 5 were frozen on dry ice. Tibiofemoral joints were
ﬁxed for 48 h in neutral buffered formalin (containing 4% par-
aformaldehyde), then decalciﬁed in 10% ethylenediaminetetraa-
cetic acid in 10 mM Tris buffer (pH 6.95) for 4 weeks at room
temperature. Coronal sections of trimmed joint tissues were
mounted in parafﬁn wax.
Joint pathology
Sections for histology were cut at 5 μm and visualised using a
20× objective lens unless otherwise indicated. Synovial lining
thickness and cellularity were scored using H&E-stained sec-
tions.30 Synovial macrophage inﬁltration was identiﬁed by
immunoreactivity for the monoclonal antibody clone ED1 direc-
ted to CD68,34 and developed with diaminobenzidine using the
glucose oxidase/nickel-enhanced method.35 The macrophage
fractional area was the percentage of synovial section area posi-
tive for CD68, derived using four ﬁelds per section and one
section per case.35 36 Mid-coronal knee sections were identiﬁed
by the presence of the cruciate ligament insertions, and stained
with Safranin-O. Osteochondral integrity was measured as the
number of channels present in the articular cartilage across the
entire medial tibial plateau of one section.2 Chondropathy and
osteophytosis were evaluated as previously described using a 4×
objective lens.2 31 All image analyses were performed by an
observer blinded to experimental details using a Zeiss Axioskop
50 microscope (Carl Zeiss, Welwyn Garden City, UK) and a
KS300 image analysis system (Image Associates, Thame, UK).
RNA extraction and cDNA synthesis
DRG were pooled to produce four separate samples from each
rat, derived from DRG innervating (L3–5) or rostral to (L1–2)
the ipsilateral or contralateral knee. Spinal cords (L1–6) were
used as control tissues due to their low levels of TrkA expres-
sion.37 Tissues were homogenised and RNA puriﬁed using the
Nucleospin RNA II Kit (Macherey-Nagel). For cDNA synthesis,
200 ng of total RNA was reverse transcribed using AfﬁnityScript
reverse transcriptase (Agilent Technologies) in a total reaction
volume of 24 mL. Reactions were incubated for 5 min at 25°C,
1 h at 50°C and terminated by incubation at 70°C for 15 min.
TaqMan quantitative real time PCR
Gene expression was quantiﬁed utilising the relative standard
curve method based on TaqMan quantitative real time PCR
(qRT-PCR). Primers and probes for β-actin were obtained from
published work,29 and those for TrkA were designed using
Primer Express software and synthesised by MWG Biotech
(Germany). Data are expressed as a ratio of gene expression
levels with reference to β-actin. TrkA forward primer: 5-GGG
AACCTGACGGAGCTCTAT-3, reverse primer: 5-ACAAAGC
GGAGGCCACTCT-3, TaqMan probe: 5-CCAGCGGGATCT
GCAACGCCT-3. β-Actin forward primer: 5-AGGCCATGTA
CGTAGCCATCCA-3, reverse primer: 5-TCTCCGGAGTCCA
TCACAATG-3, TaqMan probe: 5-TGTCCCTGTATGCCTC
TGGTCGTACCAC-3.
Statistical analysis
Data were analysed using the Statistical Package for the Social
Sciences V.16 (SPSS, Chicago, Illinois, USA) and graphically pre-
sented using Prism V.4 (GraphPad, San Diego, California, USA).
Parametric data (macrophage fractional areas (logarithmically
transformed), incapacitance and knee diameter) were analysed
using one way analysis of variance (ANOVA). Univariate com-
parisons were made against controls using the Student t test.
Non-parametric data ( joint pathology) were analysed using the
Kruskal–Wallis test followed by the Mann–Whitney test with
Bonferroni correction. Numerical data are quoted as mean
(95% CI) in the text, and, for clarity, graphically as mean±SEM
unless otherwise stated. A two-tailed p<0.05 was taken to indi-
cate statistical signiﬁcance.
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Reagents
Biotinylated rat-adsorbed horse anti-mouse antibody and
avidin–biotin complexes (ABC Kits) were from Vector
Laboratories (Peterborough, UK). Monoclonal antibody to
macrophages (clone ED1) was from Serotec (Oxford, UK).
NGFβ (N2513), indomethacin and all other chemicals were
obtained from Sigma-Aldrich (Poole, UK).
RESULTS
Intra-articular injection of NGF induces pain behaviour and
synovitis
Intra-articular injection of NGF produced, at 24 h, dose depend-
ent increases in pain behaviour (weight-bearing asymmetry and
differences in paw withdrawal thresholds; ﬁgure 1A,C),
joint swelling (ﬁgure 1E) and synovial macrophage inﬁltration
Figure 1 Nerve growth factor (NGF)-induced pain behaviour and inﬂammation in non-arthritic rat knee joints. Rat knees (n=8 rats/group) were injected
with NGF 100 ng (•), 1 mg (▪), 10 mg (▴) or saline (◊) on day 0. There was a dose dependent increase in pain behaviour, measured as the difference in
weight-bearing distribution between the hindlimbs (A and B) and paw withdrawal threshold to von Frey hair stimulation (C and D), joint swelling (E) and
synovial macrophage inﬁltration (F) 24 h after NGF injection. Pain behaviour and joint swelling had normalised to saline control levels at 24 h after
intra-articular injection of 100 ng and 1 mg NGF (A, C and E). Pain behaviour and joint swelling were increased 1 h after intra-articular injection of 10 mg
NGF in non-osteoarthritic rat knees, reached a maximum at 3 h and normalised to saline controls by days 3–5 (A–E). No statistically signiﬁcant difference
in pain behaviour measured as weight-bearing asymmetry (B) and joint swelling (E) was seen beyond day 1. Synovitis had also normalised to saline
control levels by day 7 (F). +++p<0.001 versus naive control. *p<0.05, **p<0.01, ***p<0.001 versus saline control.
1712 Ashraf S, et al. Ann Rheum Dis 2014;73:1710–1718. doi:10.1136/annrheumdis-2013-203416
Basic and translational research
 o
n
 15 January 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-203416 on 13 July 2013. Downloaded from
 
(ﬁgure 1F) in non-osteoarthritic rats. Responses returned to
control values within 3–5 days (ﬁgure 1B,D–F). On the basis of
these experiments, the 10 mg dose of NGF was selected for use
in the OA pain models.
Effects of OA on NGF-induced pain behaviour
OA pathology was fully developed 20 days after MNX or
intra-articular MIA injection, and persisted through day 35
(table 1). OA characteristics in both models were: increased pain
behaviour and joint diameter (ﬁgure 2), chondropathy, osteo-
phytosis and mild synovitis including macrophage inﬁltration of
synovium (see online supplementary table 1 and ﬁgure S3).
NGF-induced weight-bearing asymmetry was both increased
and sustained in osteoarthritic knees compared to NGF effects in
non-osteoarthritic knees. Weight-bearing asymmetry increased
2 h after NGF injection into osteoarthritic knees (MNX+NGF:
60.9 (26.8 to 95.0) g, MIA+NGF: 92.3 (61.6 to 123.0) g) com-
pared to saline-injected osteoarthritic rats (MNX: 21.1 (15.6 to
26.7) g, p<0.05; MIA: 21.5 (6.7 to 36.2) g, p<0.001). Increased
weight-bearing asymmetry was maintained 7 days after NGF
injection into osteoarthritic knees in both the MNX (58.0 (40.0
to 75.9) g) and MIA (42.4 (24.3 to 60.5) g) OA models com-
pared with saline-injected osteoarthritic rats (MNX: 18.8 (12.8
to 24.8) g, p<0.001; MIA: 13.6 (7.6 to 19.6) g, p<0.01).
NGF-induced weight-bearing asymmetry in non-osteoarthritic
rats had normalised to saline-injected controls by 1 week after
the NGF injection, whereas pain behaviour remained augmented
in NGF-injected osteoarthritic rats (ﬁgure 2A,B).
NGF injection did not further reduce paw withdrawal thresh-
olds (ﬁgure 2C,D) or further increase joint swelling (ﬁgure 2E,
F) in MIA and MNX models of OA, compared to saline-injected
osteoarthritic rats. Synovial cellularity and macrophage inﬁltra-
tion 35 days after OA induction did not differ signiﬁcantly
between knees that received NGF or saline injections on day 20
(see online supplementary ﬁgure S4).
Effects of indomethacin pretreatment on augmented
NGF-induced weight-bearing asymmetry in MIA-induced OA
Weight-bearing asymmetry was reduced during the period of
oral treatment with indomethacin (2 mg/kg once daily) from OA
induction until day 18 compared to saline-treated osteoarthritic
rats (ﬁgure 3A). After a 2-day washout (day 20), weight-bearing
asymmetry did not differ signiﬁcantly between indomethacin-
and saline-pretreated rats. Indomethacin pretreatment did,
however, inhibit the subsequent augmentation by NGF injection
of weight-bearing asymmetry in the osteoarthritic rats (40.8
(35.9 to 45.7) compared to osteoarthritic rats which had
received saline pretreatment prior to injection of NGF (67.1
(57.7 to 76.6); p<0.001) (ﬁgure 3A). Pretreatment with indo-
methacin had no signiﬁcant effects on OA-associated synovitis
measured before NGF injection (ﬁgure 3C,D). NGF injection
on day 20 was followed on day 27 by increased synovitis com-
pared with saline-injected osteoarthritic controls (ﬁgure 3E,F).
Pretreatment with indomethacin did not reduce NGF-induced
joint swelling (ﬁgure 3B), but reduced synovial macrophage
inﬁltration and synovial lining grade measured 7 days after NGF
injection into osteoarthritic knees (ﬁgures 3 and 4E,F).
Increased TrkA expression in lumbar DRG from
osteoarthritic rats and effects of indomethacin treatment
At 20 and 35 days after OA induction, TrkA expression was
increased in the ipsilateral DRG from lumbar regions (L3, 4 and
5) innervating the osteoarthritic knee joint, in both MNX and
MIA models of OA compared with non-osteoarthritic control
rats (ﬁgure 5). TrkA expression was also increased in the contra-
lateral L3, 4 and 5 DRG, and bilaterally in L1 and 2 DRG
which do not normally innervate the knee (ﬁgure S5). TrkA
expression in osteoarthritic rats was reduced following indo-
methacin treatment (ﬁgure 5). Reductions in TrkA expression
following pretreatment with indomethacin up to day 18 were
statistically signiﬁcant in L3, 4 and 5 DRG ipsilateral to the
osteoarthritic knee 20 days after OA induction (ﬁgure 5).
DISCUSSION
We demonstrate that pain behavioural responses to NGF, mea-
sured by weight-bearing asymmetry, are increased in OA knees
in two rat models. This augmented response to NGF was asso-
ciated with increased TrkA expression in lumbar DRG and
dependent on mechanisms during OA development that can be
inhibited by prior treatment with the cyclo-oxygenase inhibitor
indomethacin. Increased sensitivity to NGF may, in part, explain
the particularly encouraging analgesic effects observed in clinical
trials with NGF inhibitors in OA. Reducing sensitivity to NGF
has potential to reduce OA pain.
Injection of NGF into non-osteoarthritic rat knees was asso-
ciated with increased weight-bearing asymmetry and reduced
hindpaw withdrawal thresholds to von Frey hair stimulation
from 2 h after injection, with normalisation by day 5. Reduced
hindpaw withdrawal thresholds may indicate central sensitisa-
tion (allodynia at a site distal to the injected joint), whereas the
mechanisms underlying weight-bearing asymmetry may include
both direct nociception and central sensitisation.18 38
Comparable ﬁndings in man demonstrate that intramuscular or
subcutaneous NGF injection induces pain and both peripheral
and central sensitisation. NGF in the knee therefore may have
similar effects on pain processing as does NGF in other tissues.
Table 1 Structural changes in the meniscal transection (MNX) and monosodium iodoacetate (MIA) animal models of osteoarthritis at day 20
and 35 after induction
Structural changes
Day 20 Day 35
MNX MIA Control MNX MIA Control
Cartilage damage score (range 0–15) 9 (6–14)** 15 (5–15)*** 0 (0–1) 7 (5–11)** 12 (10–15)*** 0 (0–1)
Osteophyte score (range 0–3) 2 (1–2)* 1 (1–2)* 0 (0–0) 3 (2–3)*** 1 (1–2)* 0 (0–0)
Number of channels crossing the medial osteochondral junction 3 (3–6)* 4 (4–5)** 1 (0–2) 4 (3–5)** 4 (2–5) 1 (0–2)
% Synovial macrophage infiltration 4 (2–5)*** 3 (2–5)*** 1 (0–1) 3 (2–4)*** 2 (1–4)** 1 (1–1)
Synovial inflammation grade (range 0–3) 1 (1–1)** 1 (1–1)** 0 (0–0) 1 (1–2)* 1 (1–2)* 1 (0–1)
Values are the median (IQR) of n=8 animals/group.
*p<0.05, **p<0.01, ***p<0.001 versus controls.
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The increased weight-bearing asymmetry observed after
intra-articular NGF injection was augmented in osteoarthritic
rats compared to non-osteoarthritic rats, with respect to both
the magnitude and duration of the response. By contrast, the
increase in distal allodynia following intra-articular NGF injec-
tion was similar in osteoarthritic and non-osteoarthritic rats.
This indicates differential contributions of NGF, and the poten-
tial mechanisms underlying weight-bearing asymmetry and distal
allodynia may be differentially moderated in OA. TrkA expres-
sion was increased in DRG by 20 days after OA induction (the
time chosen for testing sensitivity to NGF), and this increased
TrkA expression persisted through day 35. Increased TrkA
expression has similarly been associated with other rodent
models of chronic pain behaviour.39 Increased TrkA expression
by sensory nerves innervating the osteoarthritic knee may con-
tribute to the augmented weight-bearing asymmetry following
intra-articular injection of NGF.
Although commonly thought of as a degenerative disease of
articular cartilage, OA in man is associated with synovitis, char-
acterised by increased synovial cellularity and macrophage inﬁl-
tration.3 4 MIA and MNX OA models similarly displayed mild
synovial macrophage inﬁltration. Cyclo-oxygenase inhibitors
Figure 2 Augmented nerve growth factor (NGF)-induced weight-bearing asymmetry, but not paw withdrawal thresholds or joint swelling, in rat
models of osteoarthritis (OA). NGF-induced pain behaviour and inﬂammation in meniscal transection (MNX) (A, C and E) and monosodium
iodoacetate (MIA) (B, D and F) models of OA. Pain behaviour, measured as increased hindlimb weight-bearing asymmetry (A and B) and reduced
paw withdrawal thresholds to punctuate mechanical stimulation (C and D), was increased 20 days after the induction of OA in rat knees by either
MNX surgery or intra-articular injection of MIA (1 mg/50 mL). In non-osteoarthritic (non-OA) rats, weight-bearing asymmetry increased 2 h following
intra-articular injection of 10 mg NGF (▵), and normalised to non-OA (saline-injected) control rats (•) by day 23 (3 days after NGF injection). In MNX
or MIA induced OA, weight-bearing asymmetry was further increased 2 h following NGF injection (MNX+NGF (▪), MIA+NGF (⋄)) compared with
saline-injected MNX (○) or MIA (▾) rats. Augmented weight-bearing asymmetry after NGF injection in osteoarthritic rats was greater than in
non-OA rats, and persisted through day 35. Pain behaviour in NGF-injected non-OA rats had normalised to controls by day 25. Intra-articular
injection of NGF reduced paw withdrawal thresholds and increased joint swelling up to 8 h after the injection in the MNX and MIA models of OA
but did not further affect paw withdrawal thresholds (C and D) or joint swelling (E and F) in these models of OA. *p<0.05, **p<0.01, ***p<0.001,
OA versus non-OA (saline-injected) controls. +p<0.05, +p<0.01, +++p<0.001, OA+NGF rats versus OA (MNX or MIA) rats. #p<0.05, ##p<0.01,
###p<0.001, OA+NGF rats versus non-OA (saline-injected) controls. Vertical broken lines indicate time of NGF injection. n=8 rats/group.
1714 Ashraf S, et al. Ann Rheum Dis 2014;73:1710–1718. doi:10.1136/annrheumdis-2013-203416
Basic and translational research
 o
n
 15 January 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-203416 on 13 July 2013. Downloaded from
 
Figure 3 Pretreatment with indomethacin in rats with monosodium iodoacetate (MIA)-induced osteoarthritis (OA) reduced the enhanced and
sustained nerve growth factor (NGF)-induced pain behaviour and synovitis, but had no signiﬁcant effects on NGF-induced joint swelling. In n=8 rats/
group, MIA (1 mg/50 mL) or saline (Sal) control was injected in left knee joints on day 0, followed by injection of either NGF (10 mg/50 mL) or saline
on day 20 (dotted line) (MIA+saline (•), saline+NGF (▪)). Pretreatment with indomethacin (Indo; 2 mg/kg, orally, daily) or saline control (vehicle (Veh))
was administered from before induction of OA to day 18. Pain behaviour measured as the difference in hindlimb weight bearing (A) was increased
following induction of OA. Injection of NGF in non-osteoarthritic (saline-injected) rats produced a short-lived pain response. Injection of NGF in OA rats
produced sustained and enhanced pain response (▵) that was reduced following pretreatment with indomethacin (□). Pretreatment with indomethacin
had no effect on OA or NGF-induced joint swelling (B). Increased synovitis as measured by synovial macrophage inﬁltration (C and E) and synovial
lining thickness/cellularity (D and F) was observed in osteoarthritic rats compared with non-arthritic controls at days 20 (C and D) and 27 (E and F) but
was not signiﬁcantly reduced following treatment with indomethacin on day 20 (C and D), before NGF injection. NGF injection on day 20 was followed
on day 27 by signiﬁcantly increased synovitis compared with saline-injected osteoarthritic controls. However, pretreatment with indomethacin
signiﬁcantly reduced the enhanced synovitis following NGF injection in rats with MIA-induced OA compared with vehicle pretreated OA rats injected
with NGF (day 27; E and F). *p<0.05, **p<0.01, ***p<0.001 versus non-osteoarthritic non-injected rats (control). +p<0.05, ++p<0.01, +++p<0.01,
vehicle-treated NGF-injected MIA (MIA+Veh+NGF) rats versus indomethacin-treated NGF-injected MIA (MIA+Indo+NGF) rats. #p<0.05, ##p<0.01,
###p<0.001, MIA+Veh+NGF treated rats versus non-osteoarthritic (saline-injected) NGF-injected (saline+NGF) rats. xp<0.05, xxp<0.01, xxxp<0.001,
osteoarthritic saline-injected (MIA+saline) rats versus non-osteoarthritic NGF-injected (saline+NGF) rats. $p<0.05, $$p<0.01, $$$p<0.001, osteoarthritic
saline-injected (MIA+saline) rats versus vehicle-treated NGF-injected MIA (MIA+Veh+NGF) rats.
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Figure 4 Effect of pretreatment with
indomethacin on nerve growth factor
(NGF)-induced synovitis. Synovitis
27 days after induction of osteoarthritis
(OA) by intra-articular injection of
monosodium iodoacetate was
measured as macrophage inﬁltration
(delineated by immunoreactivity for
CD68; A–C) and synovial lining
thickness/cellularity (arrows; D–F).
Synovitis was enhanced in
NGF-injected OA rats (A and D) at day
27. Pretreatment with indomethacin
reduced the enhanced synovitis
(synovial macrophage inﬁltration (B)
and synovial lining thickness/cellularity
(E)) following NGF injection but not to
non-osteoarthritic non-injected control
levels (C and F, respectively).
Bar=100 mm. n=8 rats/group.
Figure 5 Osteoarthritis (OA) induced increases in ipsilateral TrkA expression were reduced by pretreatment with indomethacin. Ipsilateral (A and C)
and contralateral (B and D) lumbar (L) 3, 4 and 5 dorsal root ganglia (DRG) of n=8 rats/group innervating the knee joint show a bilateral increase in
TrkA mRNA at 20 (A and B) and 35 (C and D) days after induction of OA by either transection of the meniscus (MNX) or intra-articular injection of
monosodium iodoacetate (MIA), compared with non-osteoarthritic control rats that received intra-articular saline injection on day 0 (Saline). These
effects of indomethacin were statistical signiﬁcant for ipsilateral (E) but not contralateral (F) L3, 4 and 5 DRG 20 days after OA induction by
intra-articular MIA injection. Indomethacin (Indo) (2 mg/kg, orally, daily) or saline control (vehicle (Veh)) was administered from before induction of OA
to day 18, followed by a 2-day washout period until sacriﬁce on day 20. Spinal cord tissues (L1–6) were used as controls. TrkA mRNA is normalised to
β-actin mRNA: *p<0.05, **p<0.01, ***p<0.001 versus non-osteoarthritic (saline-injected) rats. +p<0.05 versus vehicle treated MIA rats.
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such as indomethacin reduce OA pain in man, and, as in previ-
ous studies,2 40 we found that pain behaviour was reduced
during indomethacin treatment in rats with MIA-induced OA.
Following discontinuation of indomethacin, pain behaviour
returned towards that in saline-treated osteoarthritic controls,
consistent with a need for continuing treatment to maintain
analgesic efﬁcacy, which, in man, is associated with important
risk of gastrointestinal and cardiovascular adverse events.
In addition to these well-recognised effects of
cyclo-oxygenase inhibition in OA, pretreatment with indometh-
acin also reduced NGF-facilitated weight-bearing asymmetry.
This may indicate that the enhanced sensitivity to NGF seen at
day 20 in the OA models is, at least in part, dependant on
cyclo-oxygenase products. Indomethacin pretreatment also
inhibited the upregulation of TrkA mRNA in DRG ipsilateral to
the osteoarthritic knee, further supporting the hypothesis that
increased sensitivity to NGF may be due to increased TrkA
expression, which in part may depend on cyclo-oxygenase
products.
Indomethacin pretreatment may reduce sensitivity to NGF
through several mechanisms, including anti-inﬂammatory effects
in the joint, reduced afferent barrage to the spinal cord, and
direct effects on glial cells that contribute to sensitisation in rat
OA models.29 NGF-induced inﬂammation in non-articular
tissues involves mast cell degranulation and facilitated neuropep-
tide release from peripheral nerves.16 41 42 However, complete
suppression of synovitis does not appear to be necessary to
prevent increased sensitivity to NGF in OA knees, because syno-
vitis scores and synovial macrophage inﬁltration remained sig-
niﬁcantly increased in OA knees at the time of NGF injection
even after indomethacin pretreatment, and indomethacin did
not signiﬁcantly reduce joint swelling in the MIA model of OA.
The single NGF injection augmented synovitis in OA knees, and
this may have contributed to increased weight-bearing asym-
metry as both returned to levels observed in non-NGF injected
OA knees by day 35. Indomethacin pretreatment reduced the
augmented synovitis observed after NGF injection in OA knees,
and this may have contributed to reductions in weight-bearing
asymmetry.
Experimental studies in animal models have limitations.
Insufﬁcient is known about human OA to be certain that key
pathological processes are replicated in rodents. However, we
have observed similar effects of NGF in both MIA and MNX
models of OA, suggesting ﬁndings that may be generalisable to
OA itself, rather than being dependent on its mode of induction.
However, further research is required to determine whether
similar mechanisms may operate in human OA, or whether
inﬂammation, cyclo-oxygenases or other mechanisms may also
contribute to pain in other OA models. Further research would
also be required to determine whether the observed changes in
TrkA expression were the causes of altered sensitivity to NGF,
and whether contralateral and rostral increases in TrkA expres-
sion may parallel the widespread alterations in pain processing
observed in patients with OA,43 or whether increased TrkA
expression at L1–2 represents rare afferents originating from the
knee joint. Apparent differences in the effects of OA on sensitiv-
ity to NGF detected by weight-bearing asymmetry and von Frey
hair testing may be due to their non-linear measurement proper-
ties and further work would be required to conﬁrm our sugges-
tion that NGF-induced allodynia is not altered in models of OA.
Despite these reservations, however, our experiments provide
evidence that sensitivity to NGF is augmented in OA knees.
NGF blockade is efﬁcacious for OA pain in man.26 However,
signiﬁcant adverse effects on joint integrity44 have raised the
possibility that endogenous NGF may play important protective
roles in some circumstances. Better understanding of the speciﬁc
pathways through which NGF augments OA pain, including
interactions with cyclo-oxygenases, may identify targets down-
stream of NGF suitable for novel analgesic development. Our
data indicate that synovitis and increased TrkA expression may
contribute to the development of NGF sensitivity in OA.
Reducing OA-augmented sensitivity to NGF has potential to
improve OA pain while retaining the normal homeostatic
actions of NGF.
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